P171. Physiological intermolecular modification spectroscopy (PIMS) for the prediction of response to anti-TNF therapy in patients with inflammatory bowel diseases
P. Eftekhari1, L. Glaubitz2, M. Breidert3, R. Atreya4, 1INOVIEM Scientific, Bas Rhein, strasbourg, France, 2Medical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, 3Distric Hospital Kösching, Eichstätt, Teaching Hospital Technical University Munich, Kösching, Germany, 4CNRS UPR 3572, Laboratoire d'Immunopathologie et Chimie Thérapeutique, Strasbourg, France
Anti-TNF antibodies have clinical efficiency only in a subgroup of patients with inflammatory bowel diseases (IBD). Prediction of clinical responsiveness is a critical clinical problem. Physiological intermolecular modification spectroscopy (PIMS) is a label free technology, performed in physiological conditions. PIMS is a real time, dynamic molecular resonance of entire proteins and macromolecules of an individual. The aim of this study was to explore the discriminative capacity of PIMS in anti-TNF responders from non-responders in IBD.
Protein extracts of peripheral blood mononuclear cells (PBMCs) from 30 outpatients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and treated with infliximab, were subjected to PIMS analysis in a blinded transversal study. Total protein from each patient's PBMCs was challenged with infliximab. Dynamic changes in macromolecular interaction were registered while the temperature rose from −37°C to 37°C. Individual Macromolecular Volume (IMV) and Molecular Elasticity (ME) were determined for each patient.
Clinical data revealed that 67% of UC and 79% of CD patients responded to infliximab therapy during the study period of 3 months based on their respective clinical activity score. These confirmed the PIMS prediction of response or non-response to anti-TNF therapy with an accuracy of 96% respectively.
PIMS stratified IBD patients into two groups of responders and non-responders which correlated with the clinical efficacy of anti-TNF therapy. PIMS seems to be a powerful technology for adapted individualized IBD treatment. Further studies with PIMS might enable the prediction of clinical response to biological treatment in IBD patients before the therapy is initiated.